Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label extension study of pimavanserin as adjunctive treatment for schizophrenia
2016-003435-38Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pimavanserin in schizophrenia, sponsored by Acadia Pharmaceuticals. Primary endpoint: Incidence and severity of adverse events. Started Feb 2017; status: terminated.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-003435-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003435-38.